Physician profile
David Byrd
NPI 1467469197
$9,591.36
in general payments reported to CMS, 2019-2025
35 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 87% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $733 · 2021: $1,266 · 2022: $1,541 · 2023: $1,642 · 2024: $1,984 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,081 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,080.93 |
| Education | $388.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,321.93 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,169.12 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $969.52 | 2019-2025 | |
| Galderma Laboratories, L.P. | $819.55 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $810.92 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $660.90 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $588.46 | 2021-2025 | |
| Lilly USA, LLC | $303.16 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $288.16 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $283.58 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Sun Pharmaceutical Industries INC. | $265.03 | 2020-2025 | Winlevi, Absorica Ld |
| Vyne Pharmaceuticals INC. | $252.90 | 2020-2021 | |
| Journey Medical Corporation | $248.12 | 2022-2025 | |
| Ucb, INC. | $231.85 | 2020-2025 | Bimzelx |
| Almirall LLC | $204.71 | 2022-2024 | Seysara, Klisyri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $187.18 | 2023-2024 | Vtama |
| Incyte Corporation | $148.32 | 2021-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $138.32 | 2023-2025 | Zoryve |
| Biofrontera INC. | $117.82 | 2020-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $116.53 | 2019-2022 | |
| Revance Therapeutics, INC. | $95.24 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.66 | 2024-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $54.17 | 2019-2022 | |
| Genentech USA, INC. | $47.52 | 2021 | |
| Organon LLC | $42.09 | 2025 | Hadlima, Vtama |
| Prugen, INC. Pharmaceuticals | $33.50 | 2019 | |
| Epi Health, LLC | $18.68 | 2022 | |
| Organogenesis INC. | $17.96 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $17.75 | 2020 | |
| Surgenex LLC | $16.81 | 2025 | Surmatrix, Renograft, Ardeograft |
| Integra Lifesciences Corporation | $15.08 | 2021 | |
| Sensus Healthcare, INC. | $12.77 | 2019 | |
| Merck Sharp & Dohme LLC | $12.74 | 2019 | |
| Nabriva Therapeutics, Plc | $12.21 | 2021 | |
| Dermira, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.